Company intelligence / Profile preview

百极弘烨

Zhongshan City, Guangdong Province, Chinahnpa.org.cn ↗

Ownership: Private
Development stage: Other

Overview

百极弘烨 focused on innovative drug development in hematologic oncology, with a pipeline including JAK2 inhibitors for various blood cancers. There is no public record of completed clinical trials or marketed products; the company appears to have been primarily engaged in preclinical research and early-stage development before ceasing operations.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

No major partnerships publicly disclosed.

Beyond the preview

Go deeper on 百极弘烨.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 百极弘烨.

Explore the full profile